Hallmarks of pancreatic cancer: spotlight on TAM receptors

Vázquez-Bellón, Núria; Martínez Bosch, Neus; García de Frutos, Pablo; Navarro Medrano, Pilar

doi:http://dx.doi.org/10.1016/j.ebiom.2024.105278

Hallmarks of pancreatic cancer: spotlight on TAM receptors

Llicència

Citació

Vázquez-Bellón N, Martínez-Bosch N, García de Frutos P, Navarro P. Hallmarks of pancreatic cancer: spotlight on TAM receptors. EBioMedicine. 2024 Sep;107:105278. DOI: 10.1016/j.ebiom.2024.105278

Resum

Pancreatic ductal adenocarcinoma (PDAC) represents the most prevalent type of pancreatic cancer and ranks among the most aggressive tumours, with a 5-year survival rate of less than 11%. Projections indicate that by 2030, it will become the second leading cause of cancer-related deaths. PDAC presents distinctive hallmarks contributing to its dismal prognosis: (i) late diagnosis, (ii) heterogenous and complex mutational landscape, (iii) high metastatic potential, (iv) dense fibrotic stroma, (v) immunosuppressive microenvironment, and (vi) high resistance to therapy. Mounting evidence has shown a role for TAM (Tyro3, AXL, MerTK) family of tyrosine kinase receptors in PDAC initiation and progression. This review aims to describe the impact of TAM receptors on the defining hallmarks of PDAC and discuss potential future directions using these proteins as novel biomarkers for early diagnosis and targets for precision therapy in PDAC, an urgent unmet clinical need.